As of December 31, 2024, the Company had cash of approximately $6.5 million. Subsequent to December 31, 2024, the Company has sold 1,530,985 shares of common stock for net proceeds of approximately $9.9 million. Management anticipates that its cash on hand as of December 31, 2024 combined with capital raised subsequent to year-end is sufficient to fund operations into the first quarter of 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNSP:
- Moleculin, CNS, Global-e, Tenet, Summit: Trending by Analysts
- Biotech Alert: Searches spiking for these stocks today
- CNS Pharmaceuticals announces primary analysis of berubicin in GBM
- CNS Pharmaceuticals down 55% after Berubicin doesn’t show OS superiority in GBM
- Morning Movers: Mobileye jumps following Volkswagen ADAS partnership